Clinical Trials Logo
  1. Home
  2. Cocaine-Related Disorders
  3. NCT00000270
  4. Details
NCT00000270 Clinical Trial

Brain Imaging: Cocaine Effects & Medication Development - 5

Cocaine-Related Disorders Clinical Trial

Official title:
Brain Imaging: Cocaine Effects & Medication Development

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT00000270
Other study ID # NIDA-09236-5
Secondary ID 5P50DA009236-18P
Status Withdrawn
Phase Phase 4
First received September 20, 1999
Last updated August 1, 2017
Start date December 30, 1995
Est. completion date December 30, 1995

Study information
Verified date July 2017
Source New York State Psychiatric Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to define temporal profile of brain activation (rCBF) using Xenon-SPECT and O 15-PET.

Recruitment information / eligibility
Status Withdrawn
Enrollment 0
Est. completion date December 30, 1995
Est. primary completion date December 30, 1995
Accepts healthy volunteers No
Gender All
Age group 18 Years to 48 Years
Eligibility Please contact site for information.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Cocaine

Locations
Country Name City State
United States New York State Psychiatric Institute New York New York

Sponsors (2)
Lead Sponsor Collaborator
New York State Psychiatric Institute National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

References & Publications (1)

ACNP Abstract, 1995. CPDD Abstract, 1996. Society for Nuclear Medicine, 1996. Society for Neuroscience, 1997.

Outcome
Type Measure Description Time frame Safety issue
Primary Absolute change in rCBF at 5 & 15 minutes (Xe)
Primary Relative change in rCBF at 5, 19, & 33 minutes (O15)
Primary Correlated with a) subjective effects, b) venous blood level of coca, c) autonomic variables
See also
  Status Clinical Trial Phase
Completed NCT01526538 - Improving Learning-based Treatment of Cocaine Dependence With Medication Phase 2
Completed NCT00877435 - Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial N/A
Completed NCT00430690 - Acoustic Startle Reduction In Cocaine Dependence
Completed NCT00217997 - Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals N/A
Active, not recruiting NCT00094315 - Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1 Phase 1
Terminated NCT00142883 - The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3 N/A
Completed NCT00218348 - Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo Phase 2
Completed NCT00158132 - Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2 Phase 2
Completed NCT00142844 - Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 Phase 2
Completed NCT00000294 - Effects of Carvedilol on Cocaine Use in Humans - 11 Phase 2
Completed NCT00015054 - Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3 Phase 2
Completed NCT00000308 - Dextroamphetamine-Cocaine Behavioral Intervention - 5 Phase 2
Completed NCT00000306 - Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3 Phase 2
Completed NCT00000188 - Selegiline in Treatment of Cocaine Dependence - 2 Phase 2
Completed NCT00000314 - M-CPP and Fenfluramine in Cocaine Addicts - 3 Phase 2
Terminated NCT00000276 - Dopamine Reuptake Inhibitors of Cocaine Abuse - 1 Phase 1
Completed NCT00000282 - Pemoline for Cocaine Abuse - 7 Phase 2
Completed NCT00000278 - Disulfiram for Cocaine-Alcohol Abuse - 3 Phase 2
Completed NCT00000281 - Pharmacotherapy for Schizophrenic Drug Users - 6 Phase 2
Completed NCT00000277 - Mazindol for Cocaine Abuse - 2 Phase 2